Abstract
Mass Spectrometry (MS)-based technologies represent a promising area of research in clinical analysis. They are primarily concerned with measuring the relative intensity (i.e., signals) of many protein/peptide molecules associated with their mass-to-charge ratios. These measurements provide a huge amount of information which requires adequate tools to be interpreted. Following the methodology for testing hypotheses, we investigate the proteomic signals of the most common type of Renal Cell Carcinoma, the Clear Cell variant (ccRCC) [1]. By using mutual information, we detect changes in dependence values between signals from control to case groups (ccRCC or non-ccRCC). To this end, we sample and represent each population group through graphs, thus providing the observed dependence structures (many real domains are best described by relational models [2]). This way, graphs establish abstract frames of reference in our analysis giving the opportunity to test hypotheses over their properties. In other words, changes are detected by testing graph property modifications from group to group. We report the mass-to-charge values which identify bounded regions where changes have been detected. The main interest in handling such regions is to perceive which signal ranges are associated with some specific factors of interest (e.g., studying differentially expressed peaks between cases and controls) and thus, to suggest potential biomarkers for future analysis [3]. This study has been applied to samples collected at the "Ospedale Maggiore Policlinico" Foundation (Milano, Italy) using a standardized protocol. All samples were analyzed using an UltraFlex II MALDI-TOF/TOF MS instrument and mass spectra were acquired in the m=z range of 1000-12000. The samples cohort consists of 85 control subjects and 102 Renal Cell Carcinoma patients. It was possible to classify pathological group in patients affected by clear cell (ccRCC) and other different histological subtypes (respectively 79 ccRCC and 23 non-ccRCC). Table I reports the selected rejection regions (i.e., tests reject the null) at the 5% significance level. Testing hypotheses suggested by the data may induce statistical bias. For this reason, we evaluate the results to independent samples. We investigate whether test decisions are statistically independent from the region's property (i.e., distinguishing (DR) or non-distinguishing (ND) regions) when new samples are given. In other words, we want to know whether the property of a region can be statistically associated to test decisions when new samples are available. After that a new sample is provided, we verify test decisions over both the detected distinguishing regions and these regions out of the m=z bounding values previously detected. Table II summarizes the (Fisher's exact test) results confirming a significant association (α = 0.05 level) between decisions and region's property for both the class of tests. This work was supported by grants from the Italian Ministry of University and Research (PRIN n. 69373, FIRB n. RBRN07BMCT 011, FAR 2006-2011), EuroKUP COST Action (BM0702) and the NEDD project ("Regione Lombardia").
| Original language | English |
|---|---|
| Title of host publication | 2012 IEEE 2nd International Conference on Computational Advances in Bio and Medical Sciences, ICCABS 2012 |
| DOIs | |
| Publication status | Published - 2012 |
| Event | 2012 IEEE 2nd International Conference on Computational Advances in Bio and Medical Sciences, ICCABS 2012 - Las Vegas, NV, United States Duration: Feb 23 2012 → Feb 25 2012 |
Other
| Other | 2012 IEEE 2nd International Conference on Computational Advances in Bio and Medical Sciences, ICCABS 2012 |
|---|---|
| Country | United States |
| City | Las Vegas, NV |
| Period | 2/23/12 → 2/25/12 |
Fingerprint
Keywords
- bipartite graphs
- clinical data
- mass spectrometry
- mutual information
- proteomics
- test of hypothesis
ASJC Scopus subject areas
- Biomedical Engineering
- Applied Mathematics
Cite this
Poster : Characterization of distinguishing regions for renal cell carcinoma discrimination. / Zoppis, Italo; Borsani, Massimiliano; Gianazza, Erica; Chinello, Clizia; Albo, Giancarlo; Rocco, Francesco; Deelder, Andre M.; Van Der Burgt, Yuri E M; Antoniotti, Marco; Magni, Fulvio; Mauri, Giancarlo.
2012 IEEE 2nd International Conference on Computational Advances in Bio and Medical Sciences, ICCABS 2012. 2012. 6182664.Research output: Chapter in Book/Report/Conference proceeding › Conference contribution
}
TY - GEN
T1 - Poster
T2 - Characterization of distinguishing regions for renal cell carcinoma discrimination
AU - Zoppis, Italo
AU - Borsani, Massimiliano
AU - Gianazza, Erica
AU - Chinello, Clizia
AU - Albo, Giancarlo
AU - Rocco, Francesco
AU - Deelder, Andre M.
AU - Van Der Burgt, Yuri E M
AU - Antoniotti, Marco
AU - Magni, Fulvio
AU - Mauri, Giancarlo
PY - 2012
Y1 - 2012
N2 - Mass Spectrometry (MS)-based technologies represent a promising area of research in clinical analysis. They are primarily concerned with measuring the relative intensity (i.e., signals) of many protein/peptide molecules associated with their mass-to-charge ratios. These measurements provide a huge amount of information which requires adequate tools to be interpreted. Following the methodology for testing hypotheses, we investigate the proteomic signals of the most common type of Renal Cell Carcinoma, the Clear Cell variant (ccRCC) [1]. By using mutual information, we detect changes in dependence values between signals from control to case groups (ccRCC or non-ccRCC). To this end, we sample and represent each population group through graphs, thus providing the observed dependence structures (many real domains are best described by relational models [2]). This way, graphs establish abstract frames of reference in our analysis giving the opportunity to test hypotheses over their properties. In other words, changes are detected by testing graph property modifications from group to group. We report the mass-to-charge values which identify bounded regions where changes have been detected. The main interest in handling such regions is to perceive which signal ranges are associated with some specific factors of interest (e.g., studying differentially expressed peaks between cases and controls) and thus, to suggest potential biomarkers for future analysis [3]. This study has been applied to samples collected at the "Ospedale Maggiore Policlinico" Foundation (Milano, Italy) using a standardized protocol. All samples were analyzed using an UltraFlex II MALDI-TOF/TOF MS instrument and mass spectra were acquired in the m=z range of 1000-12000. The samples cohort consists of 85 control subjects and 102 Renal Cell Carcinoma patients. It was possible to classify pathological group in patients affected by clear cell (ccRCC) and other different histological subtypes (respectively 79 ccRCC and 23 non-ccRCC). Table I reports the selected rejection regions (i.e., tests reject the null) at the 5% significance level. Testing hypotheses suggested by the data may induce statistical bias. For this reason, we evaluate the results to independent samples. We investigate whether test decisions are statistically independent from the region's property (i.e., distinguishing (DR) or non-distinguishing (ND) regions) when new samples are given. In other words, we want to know whether the property of a region can be statistically associated to test decisions when new samples are available. After that a new sample is provided, we verify test decisions over both the detected distinguishing regions and these regions out of the m=z bounding values previously detected. Table II summarizes the (Fisher's exact test) results confirming a significant association (α = 0.05 level) between decisions and region's property for both the class of tests. This work was supported by grants from the Italian Ministry of University and Research (PRIN n. 69373, FIRB n. RBRN07BMCT 011, FAR 2006-2011), EuroKUP COST Action (BM0702) and the NEDD project ("Regione Lombardia").
AB - Mass Spectrometry (MS)-based technologies represent a promising area of research in clinical analysis. They are primarily concerned with measuring the relative intensity (i.e., signals) of many protein/peptide molecules associated with their mass-to-charge ratios. These measurements provide a huge amount of information which requires adequate tools to be interpreted. Following the methodology for testing hypotheses, we investigate the proteomic signals of the most common type of Renal Cell Carcinoma, the Clear Cell variant (ccRCC) [1]. By using mutual information, we detect changes in dependence values between signals from control to case groups (ccRCC or non-ccRCC). To this end, we sample and represent each population group through graphs, thus providing the observed dependence structures (many real domains are best described by relational models [2]). This way, graphs establish abstract frames of reference in our analysis giving the opportunity to test hypotheses over their properties. In other words, changes are detected by testing graph property modifications from group to group. We report the mass-to-charge values which identify bounded regions where changes have been detected. The main interest in handling such regions is to perceive which signal ranges are associated with some specific factors of interest (e.g., studying differentially expressed peaks between cases and controls) and thus, to suggest potential biomarkers for future analysis [3]. This study has been applied to samples collected at the "Ospedale Maggiore Policlinico" Foundation (Milano, Italy) using a standardized protocol. All samples were analyzed using an UltraFlex II MALDI-TOF/TOF MS instrument and mass spectra were acquired in the m=z range of 1000-12000. The samples cohort consists of 85 control subjects and 102 Renal Cell Carcinoma patients. It was possible to classify pathological group in patients affected by clear cell (ccRCC) and other different histological subtypes (respectively 79 ccRCC and 23 non-ccRCC). Table I reports the selected rejection regions (i.e., tests reject the null) at the 5% significance level. Testing hypotheses suggested by the data may induce statistical bias. For this reason, we evaluate the results to independent samples. We investigate whether test decisions are statistically independent from the region's property (i.e., distinguishing (DR) or non-distinguishing (ND) regions) when new samples are given. In other words, we want to know whether the property of a region can be statistically associated to test decisions when new samples are available. After that a new sample is provided, we verify test decisions over both the detected distinguishing regions and these regions out of the m=z bounding values previously detected. Table II summarizes the (Fisher's exact test) results confirming a significant association (α = 0.05 level) between decisions and region's property for both the class of tests. This work was supported by grants from the Italian Ministry of University and Research (PRIN n. 69373, FIRB n. RBRN07BMCT 011, FAR 2006-2011), EuroKUP COST Action (BM0702) and the NEDD project ("Regione Lombardia").
KW - bipartite graphs
KW - clinical data
KW - mass spectrometry
KW - mutual information
KW - proteomics
KW - test of hypothesis
UR - http://www.scopus.com/inward/record.url?scp=84860517197&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860517197&partnerID=8YFLogxK
U2 - 10.1109/ICCABS.2012.6182664
DO - 10.1109/ICCABS.2012.6182664
M3 - Conference contribution
AN - SCOPUS:84860517197
SN - 9781467313216
BT - 2012 IEEE 2nd International Conference on Computational Advances in Bio and Medical Sciences, ICCABS 2012
ER -